We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day. This change outpaced the S&P 500's 0.03% loss on the day. Meanwhile, the Dow experienced a drop of 0.31%, and the technology-dominated Nasdaq saw an increase of 0.01%.
Heading into today, shares of the drugmaker had lost 5.66% over the past month, lagging the Medical sector's loss of 4.15% and the S&P 500's gain of 0.53%.
Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company is expected to report EPS of $4.84, up 0.83% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.4 billion, up 10.43% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $18.86 per share and a revenue of $13.21 billion, demonstrating changes of +2.5% and +10.08%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.04% downward. At present, Vertex Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is currently trading at a Forward P/E ratio of 27.38. This expresses a premium compared to the average Forward P/E of 25.2 of its industry.
Meanwhile, VRTX's PEG ratio is currently 2. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. VRTX's industry had an average PEG ratio of 1.91 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 174, placing it within the bottom 30% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Vertex Pharmaceuticals (VRTX - Free Report) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day. This change outpaced the S&P 500's 0.03% loss on the day. Meanwhile, the Dow experienced a drop of 0.31%, and the technology-dominated Nasdaq saw an increase of 0.01%.
Heading into today, shares of the drugmaker had lost 5.66% over the past month, lagging the Medical sector's loss of 4.15% and the S&P 500's gain of 0.53%.
Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company is expected to report EPS of $4.84, up 0.83% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.4 billion, up 10.43% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $18.86 per share and a revenue of $13.21 billion, demonstrating changes of +2.5% and +10.08%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.04% downward. At present, Vertex Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is currently trading at a Forward P/E ratio of 27.38. This expresses a premium compared to the average Forward P/E of 25.2 of its industry.
Meanwhile, VRTX's PEG ratio is currently 2. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. VRTX's industry had an average PEG ratio of 1.91 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 174, placing it within the bottom 30% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.